Lakefront (GLPG) Barclays 27th Annual Global Healthcare Conference presentation summary

Strategic transformation and separation

• Plans underway to separate into two publicly traded entities, each with distinct focus areas and strategies to maximize growth and shareholder value.

• One entity will focus on global oncology leadership in cell therapies, while the other (SpinCo) will build a pipeline in oncology, immunology, and virology through acquisitions and licensing.

• SpinCo will assume the collaboration agreement with Gilead and continue to leverage their expertise.

• Each company will have autonomy to allocate resources and pursue tailored strategies.

• All shareholders will receive SpinCo shares proportional to their current holdings.

Innovation in cell therapy and manufacturing

• Decentralized manufacturing model enables scalable, consistent production of fresh cell therapies near clinics, reducing logistical and cost burdens.

• The Cocoon® Platform provides automated, closed-system cell culture, supporting GMP compliance and global scalability.

• Next-generation, multi-targeting, armored cell therapies are being developed for hematological and solid tumors.

• Strengthening US capabilities in preparation for the launch of the first CAR-T therapy.

Clinical pipeline and efficacy data

• Robust cell therapy pipeline includes CD19 CAR-T (GLPG5101), BCMA CAR-T, and TCR-T programs targeting high unmet needs in hematological and solid tumors.

• ATALANTA-1 study shows high response rates: 100% CR in MCL, 95% in FL/MZL, and 54% in DLBCL (71% at higher dose).

• Durable responses observed, with 80% of evaluable CR patients being MRD negative and remaining in CR at data cutoff.

• Manageable safety profile for GLPG5101, with only isolated Grade 3 adverse events.